by MM360 Staff | May 23, 2025 | Myeloma News
Source: Pharmacy Times articles Orforglipron showed promising results in managing type 2 diabetes, offering a potential oral alternative to injectable treatments. Read More
by MM360 Staff | May 23, 2025 | Featured News, Myeloma News
Regeneron Pharmaceuticals has announced promising initial results from its Phase 1b LINKER-MM2 trial, evaluating linvoseltamab in combination with proteasome inhibitors carfilzomib or bortezomib for patients with relapsed/refractory multiple myeloma (R/R MM). These...
by MM360 Staff | May 23, 2025 | Featured News, Myeloma News
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) has voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a monotherapy for adults with high-risk smoldering multiple myeloma...
by MM360 Staff | May 22, 2025 | Myeloma News
Source: Pharmacy Times articles Mepolizumab gains FDA approval as a promising add-on therapy for COPD patients with eosinophilic phenotype, reducing exacerbation rates significantly. Read More
by MM360 Staff | May 22, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | May 22, 2025 | Myeloma News
Source: Pharmacy Times articles Senate, President Trump must also act soon to finally end spread pricing and reimbursement games in Medicaid, NCPA says Read More
